Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal of Oncology Practice|September 23, 2010
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancerRuth Oratz, Dev Paul, Allen L Cohn, et al.Oncotargets and Therapy|March 4, 2017
BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening studyAllen L Cohn, Bann-Mo Day, Sarang Abhyankar, et al.JCO Precision Oncology|March 12, 2026
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes AnalysisCharles Swanton, Alan Bryce, Allen L Cohn, et al.Investigational New Drugs|February 29, 2008
A phase II study of pemetrexed in patients with advanced hepatocellular carcinomaAllen L Cohn, J William Myers, Steven Mamus, et al.Pharmacoepidemiology and Drug Safety|May 17, 2014
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort studyAxel Grothey, E Dawn Flick, Allen L Cohn, et al.Clinical Colorectal Cancer|August 23, 2011
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancerAllen L Cohn, Grace C Shumaker, Pankaj Khandelwal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesRoger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, et al.The Oncologist|September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyJohanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2023
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety UpdateVicky Makker, Carol Aghajanian, Allen L Cohn, et al.Pageof 3